Insights & news

OECD - Pharmaceutical Innovation and Access to Medicines

  • 30/11/2018
  • Articles

The Organisation for Economic Cooperation and Development (“OECD”) has just published a study on Pharmaceutical Innovation and Access to Medicines (the “Study” - available here: Pharmaceutical Innovation and Access to Medicines). The Study forms a response to a request by 35 member countries to prepare a report detailing the challenges for governments in ensuring that their populations have access to novel medicines at a reasonable cost while at the same time maintaining the pharmaceutical sector’s capacity for innovation.
The Study offers a three-pronged answer in describing, firstly, the performance of the current system, before, secondly, determining five broad principles that the OECD believes should inform its member countries’ policies and, thirdly, offering five concrete policy options.


Broad Principles        
The five principles which, according to the OECD, should always guide member countries in defining their health policies are: 

  • Increasing the value of spending on medicines.
  • Ensuring access in countries at different levels of development by applying and/or maintaining “tiered” or differential pricing.
  • Maintaining a rules-based system.
  • Fostering competition in both on-patent and off-patent markets.
  • Promoting better communication among stakeholders on matters such as industry activities, costs of research and development and forthcoming products. 

Policy Options
Against this backdrop, the Study puts forward the following policy options: 

  • Involving stakeholders in efforts to reduce the cost of research and development and accelerate market access.
  • Increase spending efficiency – This covers a broad category of possible measures, including vexed issues such as cooperation in health technology assessment and collaborative efforts in price negotiations and procurement (provided member countries are of similar income level), but also measuring the actual performance of reimbursed medicines. The Study furthermore advocates increased competition in both on-patent and off-patent markets and is also a proponent of bundled payments for episodes of care.
  • Determine willingness to pay for new treatments – One significant aspect under this rubrique is optimising the use of Managed Entry Agreements. For example, outcomes should be better defined and measured, while the results should be shared with the scientific community, prescribers and patients.
  • Develop new incentives for innovation.
  • Strengthen the information base.         


Key contacts

Related practice areas

Related insights

Sign up for updates
    • 03/12/2018
    • Articles

    Five Further Member State Inspectorates Recognised under EU - US Mutual Recognition System for Medicines

    The Agreement on Mutual Recognition between the European Union and the United States of America continues its roll-out in the realm of pharmaceutical inspections. On two separate occasions in November 2018, the US Food and Drug Administration (“FDA”) added 5 new EU Member States to its list of countries which it considers to have capable inspectorates to carry out good manufacturing practice (“GMP”) inspections at a level equivalent to that observed in the US. These Member States are Belgium, Denmark, Estonia, Finland and Latvia. The updated list of in total 20 Member States whose inspection results the FDA considers can replace its own inspections can be found here: The EU and the US thus seem to be on track to have all EU Member States recognised as capable of carrying out pharmaceutical inspections by 15 July 2019. For its part, the FDA had already been earmarked as a capable inspectorate on 1 November 2017.

    Read more
    • 22/11/2018
    • Articles

    "National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine" Says ECJ

    The Court of Justice of the European Union (“ECJ”) held this morning that under EU law national healthcare insurance systems are allowed to reimburse a medicine for a use not covered by that product’s marketing authorisation (see attached – Case C-29/17, Novartis and others v. Agenzia Italiana del Farmaco and others, judgment of 21 November 2018). The ECJ’s judgment came at the request of the Italian Council of State which had been asked to handle litigation between Novartis and various Italian health authorities over the reimbursement of Avastin for off-label use in the management of the eye-condition wet age-related macular degeneration (“AMD”).

    Read more
    • 16/11/2018
    • Articles

    Novelties regarding Clinical Trials - Law of 30 October 2018 containing Miscellaneous Provisions regarding Health

    The Belgian Official Journal publishes today a Law of 30 October 2018 containing miscellaneous provisions regarding health. The attached case note sheds light on new rules governing clinical trials.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *